REGENX Biosciences, LLC today announced that gene transfer mediated by REGENX's NAV® AAV9 vector can be accomplished in vivo and globally correct central nervous system (CNS) manifestations of MPS I, ...

WASHINGTON, DC and PARIS, FRANCE--(Marketwired - Apr 29, 2014) - REGENX Biosciences, LLC announces that the company has entered into an agreement with AAVLife for the development and commercialization ...

WASHINGTON, DC and DALLAS, TX--(Marketwired - Apr 1, 2014) - REGENX Biosciences, LLC (REGENX) and AveXis, Inc. (AveXis) announce that they have entered into an exclusive agreement for the development ...

ROCKVILLE, Md., July 31, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy ...

EK is releasing two EK-Vector Radeon RX 5700 +XT water blocks that are compatible with reference design Radeon RX 5700 and 5700 XT graphics cards. This efficient and elegant-looking cooling will allow ...

Voyager Therapeutics has exercised commercial options for the use of Regenxbio’s NAV ® vectors to develop and commercialize gene therapies for specific neurological diseases, the companies said today.

Voyager Therapeutics has entered a license agreement with ReGenX to use the gene therapy firm's NAV® vectors to develop and commercialize gene therapies to treat amyotrophic lateral sclerosis (ALS), ...

“Rocket is delighted to partner with REGENXBIO to advance our first gene therapy product derived from the NAV Technology Platform, reinforcing the potential of our disease-focused, multi-platform ...

ROCKVILLE, Md., July 24, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy ...

REGENXBIO (NASDAQ:RGNX) extends a global exclusive license to AveXis (AVXS) to develop and commercialize gene therapies using RGNX's NAV AAV9 vector to treat Rett Syndrome and a form of amyotrophic ...